BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 20429308)

  • 1. Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic.
    Reuss-Borst M; Hartmann U; Scheede C; Weiß J
    Osteoporos Int; 2012 Apr; 23(4):1437-44. PubMed ID: 21755400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
    Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.
    Jones S; Stokoe C; Sborov M; Braun M; Ethirajan S; Kutteh L; Pippen J; Patel M; Paul D; Blum JL; Holmes FA; Myron MC; Cantrell J; Hartung NL; Look RM; Di Salle E; Davis JC; Ilegbodu D; Asmar L
    Clin Breast Cancer; 2008 Dec; 8(6):527-32. PubMed ID: 19073509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
    Markopoulos C; Koukouras D; Venizelos V; Karyda I; Xepapadakis G; Misitzis J; Kalogerakos K; Poulakaki F; Natsiopoulos J; Zobolas V; Savidou C; Antonopoulou Z; Tzoracoleftherakis E
    Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy.
    Kwan ML; Yao S; Laurent CA; Roh JM; Quesenberry CP; Kushi LH; Lo JC
    Breast Cancer Res Treat; 2018 Apr; 168(2):523-530. PubMed ID: 29249058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone mineral density in early breast cancer patients.
    Spanik S; Spanikova B
    Bratisl Lek Listy; 2010; 111(1):27-32. PubMed ID: 20429308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.